Novo Nordisk’s Oral Wegovy Gets UK Nod as Cyber Breach Casts a Shadow
13.06.2026 - 07:53:47 | boerse-global.de
It has been a year since Novo Nordisk’s shares touched an all-time high above €70. Now trading at barely €38, the stock has shed roughly 45% of its value – a decline that underscores just how much the GLP-1 landscape has shifted. Against that backdrop, the past week delivered two starkly contrasting headlines on the same day: a landmark European approval for an oral version of Wegovy, and a cyber attack that exposed sensitive patient and doctor data.
Pill approval breaks new ground in Europe
The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) granted marketing authorisation for oral semaglutide on 12 June, making Britain the first European country to clear the daily tablet. Previously only the United States and the United Arab Emirates had given the green light. The decision is a strategic coup for Novo Nordisk, as many patients shy away from injections and the pill format could unlock a much wider customer base.
The approval rests on the OASIS-4 trial, in which participants taking the 25 mg daily dose lost an average of 16.6% of their body weight over 64 weeks, compared with 2.2% in the placebo group. The drug is expected to be available on private prescription within weeks, and industry analysts forecast that more than 120,000 patients in the UK could be treated in the first three months. The UK’s National Health Service is currently reviewing whether to broaden reimbursement coverage.
Hackers steal clinical trial data
On the same day the MHRA announcement landed, Novo Nordisk confirmed a data security incident. Attackers gained access to internal systems on 11 June and exfiltrated files containing pseudonymised patient data from several clinical studies – including participant IDs, years of birth, biomarkers and lifestyle factors.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
More worrying is the second tranche of stolen information: identifiable data on doctors and medical staff, such as names, registration numbers, email addresses, phone numbers and office addresses. That combination raises the risk of targeted phishing campaigns. The company stated that its core business operations remain unaffected. External cybersecurity experts are investigating the breach, and Novo Nordisk now faces potential regulatory scrutiny and reputational damage.
Stock stabilises but remains under pressure
Novo Nordisk shares closed the week at €38.03, virtually flat on the day but up a little over 2% for the week. That recovery, however, is fragile. The stock has lost roughly 15% since the start of the year, and at €38.14 currently sits about 8% below its 200-day moving average of €41.43. The relative strength index of 53.6 points to neutral momentum, and while the price has climbed back above the 50-day line since hitting a March low of €30.25, the technical picture does not yet signal a sustained turnaround.
Growing competition and US cost pressures
Beyond the immediate headlines, fundamental headwinds continue to weigh on the outlook. The GLP-1 market is booming, drawing an ever-growing list of competitors and intensifying price pressure. In the United States, some employers have indicated they will stop covering expensive weight-loss injections from 2027, a move that could severely crimp future demand.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
On the positive side, France has announced it will reimburse obesity medications, adding a fresh growth driver in Europe. Meanwhile, Novo Nordisk’s M&A chief, John McDonald, is leaving after eight years to join Forbion as an operating partner. He oversaw the acquisitions of Embark Biotech and Inversago Pharma, but a successor has not been named and no major deal has been announced this year – a sign that the company is prioritising its internal GLP-1 pipeline over external purchases.
The cautious message from the market is clear: the oral Wegovy approval is a genuine milestone, but it does not cancel out the mounting competitive and pricing risks. Novo Nordisk must now demonstrate that its growth story is robust enough to withstand the forces that brought the stock down from its peak.
Ad
Novo Nordisk Stock: New Analysis - 13 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
